A collaboration on cancer immunotherapy

CMBG and GE Healthcare have entered a strategic collaboration to develop industrial control processes in CAR-T and stem cell manufacturing.


Cellular Biomedicine Group Inc. (CBMG), a clinical-stage biopharmaceutical firm, has established a strategic research collaboration with GE Healthcare Life Sciences China. The collaboration focuses on developing high-quality industrial control processes in chimeric antigen receptor T cell (CAR-T) and stem cell manufacturing.

A new laboratory within CBMG's new Shanghai Zhangjiang GMP-facility will be established and dedicated to the joint research and development of a functionally integrated and automated immunotherapy cell preparation system.

CBMG and GE Healthcare Life Sciences China plan to develop state-of-the-art automated CAR-T and stem cell manufacturing capabilities that build upon the accreditation of CBMG's GMP facilities in Shanghai, Wuxi and Beijing. The co-development activity will aim to standardize the delivery of cell manufacturing to potentially improve throughput, alleviate cost burdens and to minimize variability in cell production, which may increase the availability of engineered cells upon commercialization.

This partnership combines CBMG's scientific expertise in the manufacturing of CAR-T and stem cell production in China and GE Healthcare's renowned expertise in the design and development of innovative manufacturing technologies for the biopharmaceutical industry.

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email